Effects of CDR132L on cardiac structure and function in heart failure with preserved ejection fraction and left ventricular hypertrophy: the 8212-Preserved trial

10 May 2026 (16:30 - 17:15)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Professor Rudolf De Boer

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail

Ventricular remodeling phenotypes following intermittent levosimendan therapy in advanced heart failure

Doctor R. Fernandes Da Silva (Evora, PT)

Abstract Slides

Presentation thumbnail

Left ventricular remodeling and fibrosis indices are strongly associated with soluble ST2 but not with NTproBNP in patients with HFrEF: a comparative analysis

Doctor A. Ntalianis (Athens, GR)

Abstract Slides

Presentation thumbnail

A parsimonious echocardiography-based model for long-term mortality risk stratification in heart failure with preserved ejection fraction

Doctor L. Mi (Beijing, CN)

Abstract Slides

Presentation thumbnail

The role of diastolic dysfunction in heart failure with reduced ejection fraction (HFrEF)

Professor E. Jones (Leuven, BE)

Abstract Slides

Presentation thumbnail

Right atrial stiffness index predicts mortality in pulmonary hypertension when standard atrial metrics fail

Doctor A. Pearlman (Melbourne, AU)

Abstract Slides

Access the full session

Session thumbnail

Echocardiographic evaluation of mechanisms in heart failure

The Event

Event poster

Heart Failure 2026

10 May 2026 16:30 CET

You may be interested in

Congress Session

Clinical phenotypes of heart failure with preserved ejection fraction

Webinar

Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction

Webinar

Acute heart failure in patients with preserved ejection fraction (AHFPEF)

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources